Multimodal diagnostics in multiple sclerosis: predicting disability and conversion from relapsing-remitting to secondary progressive disease course – protocol for systematic review and meta-analysis
暂无分享,去创建一个
M. Ljubisavljevic | M. Szólics | J. Gelovani | T. Arora | K. M. Das | Y. Statsenko | Linda Östlundh | T. Habuza | T. Almansoori | Tatsiana Talako | K. Gorkom | Fatmah Al Zahmi | Fransina Christina King | G. Simiyu | Darya Smetanina | Sarah Meribout | F. Ismail | Iryna Makhnevych | Yauhen Statsenko | K. Gorkom
[1] M. Schoonheim,et al. Serum neurofilament light chain predicts cognitive worsening in secondary progressive multiple sclerosis better than brain MRI measures , 2022, Multiple sclerosis.
[2] A. Heslegrave,et al. Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial , 2022, Multiple sclerosis.
[3] L. Airas,et al. Innate Immune Cell–Related Pathology in the Thalamus Signals a Risk for Disability Progression in Multiple Sclerosis , 2022, Neurology: Neuroimmunology & Neuroinflammation.
[4] A. Berardelli,et al. Are Neurophysiological Biomarkers Able to Discriminate Multiple Sclerosis Clinical Subtypes? , 2022, Clinical Neurophysiology.
[5] K. Hoshi,et al. Assisting the diagnosis of multiple sclerosis using a set of regional brain volumes: A classification model for patients and healthy controls , 2021, Informatics in Medicine Unlocked.
[6] T. Berger,et al. Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review , 2021, Frontiers in Neurology.
[7] P. Cuijpers,et al. Doing Meta-Analysis with R , 2021 .
[8] M. Filippi,et al. Spinal Fluid Myeloid Microvesicles Predict Disease Course in Multiple Sclerosis , 2021, Annals of neurology.
[9] N. Toschi,et al. Cortical and phase rim lesions on 7 T MRI as markers of multiple sclerosis disease progression , 2021, Brain communications.
[10] Mehmet Feyzi Aksahin,et al. Detection of multiple sclerosis from photic stimulation EEG signals , 2021, Biomed. Signal Process. Control..
[11] Elena Garcia-Martin,et al. Machine learning in diagnosis and disability prediction of multiple sclerosis using optical coherence tomography , 2021, Comput. Biol. Medicine.
[12] R. Deichmann,et al. Multiparametric Quantitative MRI in Neurological Diseases , 2021, Frontiers in Neurology.
[13] M. Forsting,et al. Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography , 2021, Journal of Neuro-Oncology.
[14] E. Leray,et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition , 2020, Multiple sclerosis.
[15] L. Airas,et al. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis , 2020, Brain : a journal of neurology.
[16] Leila Akramian Arani,et al. Development of a Knowledge-based Clinical Decision Support System for Multiple Sclerosis Diagnosis , 2020, Journal of medicine and life.
[17] M. Freedman,et al. Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years , 2020, Multiple sclerosis journal - experimental, translational and clinical.
[18] Mário João Fartaria,et al. RimNet: A deep 3D multimodal MRI architecture for paramagnetic rim lesion assessment in multiple sclerosis , 2020, NeuroImage: Clinical.
[19] Bryan R. Smith,et al. Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study , 2020, Annals of neurology.
[20] D. Arnold,et al. Serum neurofilament light as a biomarker in progressive multiple sclerosis , 2020, Neurology.
[21] M. Filippi,et al. Identifying Progression In Multiple Sclerosis: New Perspectives. , 2020, Annals of neurology.
[22] M. Dwyer,et al. MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. , 2020, Expert review of neurotherapeutics.
[23] Andrea Zaccaria,et al. Considering patient clinical history impacts performance of machine learning models in predicting course of multiple sclerosis , 2020, PloS one.
[24] Giuseppe M Sechi,et al. Prevalence of multiple sclerosis in Sardinia: A systematic cross-sectional multi-source survey , 2020, Multiple sclerosis.
[25] T. Vollmer,et al. Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides , 2020, PloS one.
[26] L. Airas,et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity , 2020, Multiple sclerosis.
[27] A. Haghdoost,et al. Incidence of multiple sclerosis in Iran: a nationwide, population-based study. , 2019, Public health.
[28] D. Ramasamy,et al. Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. , 2019, Radiology.
[29] G. Chiang. Atrophied T2 Lesion Volume in Multiple Sclerosis: Reducing the Focus on Lesion Counting. , 2019, Radiology.
[30] R. Meuli,et al. The “central vein sign” in patients with diagnostic “red flags” for multiple sclerosis: A prospective multicenter 3T study , 2019, Multiple sclerosis.
[31] T. Ziemssen,et al. A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition , 2019, Journal of Neurology.
[32] Klara Novotna,et al. Slowed articulation rate is associated with information processing speed decline in multiple sclerosis: A pilot study , 2019, Journal of Clinical Neuroscience.
[33] Elena Garcia-Martin,et al. Swept source optical coherence tomography to early detect multiple sclerosis disease. The use of machine learning techniques , 2019, PloS one.
[34] M. Inglese,et al. Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers , 2019, EJNMMI Radiopharmacy and Chemistry.
[35] R. Barea,et al. A computer-aided diagnosis of multiple sclerosis based on mfVEP recordings , 2019, PloS one.
[36] J. Sipilä,et al. Multiple sclerosis epidemiology in Finland: Regional differences and high incidence , 2019, Acta neurologica Scandinavica.
[37] M. Morgan,et al. Multiple challenges for people after transitioning to secondary progressive multiple sclerosis: a qualitative study , 2019, BMJ Open.
[38] C. Morgan,et al. Meta-analysis for diagnostic tests , 2018, Journal of Nuclear Cardiology.
[39] J. Vistbakka. Circulating microRNAs as biomarkers in multiple sclerosis , 2018 .
[40] Josué Luiz Dalboni da Rocha,et al. Characterization of relapsing-remitting multiple sclerosis patients using support vector machine classifications of functional and diffusion MRI data , 2018, NeuroImage: Clinical.
[41] M. Hutchinson,et al. 2017 McDonald diagnostic criteria: A review of the evidence. , 2018, Multiple sclerosis and related disorders.
[42] M. Calabrese,et al. The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis , 2018, Neurology.
[43] Michael Deppe,et al. Non-lesional cerebellar damage in patients with clinically isolated syndrome: DTI measures predict early conversion into clinically definite multiple sclerosis☆ , 2018, NeuroImage: Clinical.
[44] I. Cerovečki,et al. Prevalence of multiple sclerosis in Croatia: data from national and non-governmental organization registries , 2018, Croatian medical journal.
[45] R. Marrie,et al. Establishing the Incidence and Prevalence of Multiple Sclerosis in Saskatchewan , 2018, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[46] G. Nasios,et al. Cognitive and Language Deficits in Multiple Sclerosis: Comparison of Relapsing Remitting and Secondary Progressive Subtypes , 2018, The open neurology journal.
[47] P. Matthews,et al. Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis , 2017, Brain : a journal of neurology.
[48] M. Barnett,et al. Exosomal microRNA signatures in multiple sclerosis reflect disease status , 2017, Scientific Reports.
[49] Roger C. Tam,et al. Deep learning of joint myelin and T1w MRI features in normal-appearing brain tissue to distinguish between multiple sclerosis patients and healthy controls , 2017, NeuroImage: Clinical.
[50] D. Chard,et al. Resolving the clinico-radiological paradox in multiple sclerosis , 2017, F1000Research.
[51] K. Selmaj,et al. Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis , 2017, Annals of neurology.
[52] M. Calabrese,et al. Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study , 2017, Multiple sclerosis.
[53] D. Reich,et al. FLAIR* to visualize veins in white matter lesions: A new tool for the diagnosis of multiple sclerosis? , 2017, European Radiology.
[54] J. Rinne,et al. Imaging of microglial activation in MS using PET: Research use and potential future clinical application , 2017, Multiple sclerosis.
[55] David H. Miller,et al. Diagnosis of multiple sclerosis: progress and challenges , 2017, The Lancet.
[56] F. X. Aymerich,et al. Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI , 2017, European Radiology.
[57] T. Lehtimäki,et al. Circulating microRNAs as biomarkers in progressive multiple sclerosis , 2017, Multiple sclerosis.
[58] A. Edwards,et al. The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' Experiences. , 2016, International journal of MS care.
[59] Gerta Rücker,et al. Modelling multiple thresholds in meta-analysis of diagnostic test accuracy studies , 2016, BMC Medical Research Methodology.
[60] M. Ban,et al. Age Related Multiple Sclerosis Severity Score: Disability ranked by age , 2017, Multiple sclerosis.
[61] D. Reich,et al. Clinical 3-tesla FLAIR* MRI improves diagnostic accuracy in multiple sclerosis , 2016, Multiple sclerosis.
[62] F. Barkhof,et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients , 2015, Nature Reviews Neurology.
[63] R. Parkkola,et al. In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand 11C-PK11195 , 2014, The Journal of Nuclear Medicine.
[64] Jimmy Singla,et al. Medical Expert Systems for Diagnosis of Various Diseases , 2014 .
[65] L. Kappos,et al. Improved Characterization of Visual Evoked Potentials in Multiple Sclerosis by Topographic Analysis , 2013, Brain Topography.
[66] N. Karimi,et al. Vestibular evoked myogenic potential for diagnoses of multiple sclerosis: is it beneficial? , 2013, Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina.
[67] M. Horsfield,et al. Microstructural magnetic resonance imaging of cortical lesions in multiple sclerosis , 2013, Multiple sclerosis.
[68] M. Calabrese,et al. Grey matter lesions in MS , 2013, Prion.
[69] P. Matthews,et al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability , 2012, Neurology.
[70] Gang Huang,et al. Comparison of virtual cystoscopy and ultrasonography for bladder cancer detection: a meta-analysis. , 2011, European journal of radiology.
[71] Zhengliang Xu,et al. Real-time elastography for the differentiation of benign and malignant breast lesions: a meta-analysis , 2011, Breast Cancer Research and Treatment.
[72] Massimo Filippi,et al. MR imaging of multiple sclerosis. , 2011, Radiology.
[73] P. Arnett,et al. Cognitive and neurobehavioral features in multiple sclerosis , 2011, Expert review of neurotherapeutics.
[74] A. Feinstein,et al. Validity of a computerized version of the Symbol Digit Modalities Test in multiple sclerosis , 2011, Journal of Neurology.
[75] Bin Zhang,et al. Comparison of multifocal visual evoked potential, standard automated perimetry and optical coherence tomography in assessing visual pathway in multiple sclerosis patients , 2010, Multiple sclerosis.
[76] G. Onder,et al. Correlation between disability and transcranial magnetic stimulation abnormalities in patients with multiple sclerosis , 2009, Journal of Clinical Neuroscience.
[77] J. C. Houwelingen,et al. Bivariate Random Effects Meta-Analysis of ROC Curves , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.
[78] G. Johnson,et al. Diffusion tensor imaging in multiple sclerosis: assessment of regional differences in the axial plane within normal-appearing cervical spinal cord. , 2006, AJNR. American journal of neuroradiology.
[79] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[80] E. İdiman,et al. Cortical silent period and motor evoked potentials in patients with multiple sclerosis , 2003, Clinical Neurology and Neurosurgery.
[81] F. Barkhof. The clinico‐radiological paradox in multiple sclerosis revisited , 2002, Current opinion in neurology.
[82] L. Leocani,et al. Neurophysiological investigations in multiple sclerosis. , 2000, Current opinion in neurology.
[83] S. Shapiro,et al. An Analysis of Variance Test for Normality (Complete Samples) , 1965 .
[84] Megan Sorenson,et al. Library , 1958 .
[85] C. Lortie. Doing Meta-Analysis with R - A Hands-On Guide , 2022, J. Stat. Softw..
[86] M. Maghbooli,et al. Diagnostic value of DWI-MRI for the detection of acute plaques in the relapse phase of multiple sclerosis , 2021 .
[87] U. Sakoglu,et al. Multiple sclerosis lesion detection in multimodal MRI using simple clustering-based segmentation and classification , 2020 .
[88] T. Filleron. Comparing sensitivity and specificity of medical imaging tests when verification bias is present: The concept of relative diagnostic accuracy. , 2018, European journal of radiology.
[89] Heinz Holling,et al. Meta-Analysis of Diagnostic Accuracy with mada , 2017 .
[90] Gabriele C DeLuca,et al. Cognitive Impairment in Multiple Sclerosis: Clinical, Radiologic and Pathologic Insights , 2015, Brain pathology.
[91] Gerta Rücker,et al. Meta-Analysis of Diagnostic Test Accuracy Studies , 2015 .
[92] M. Napierala. What Is the Bonferroni Correction ? , 2014 .
[93] Package 'metafor' , 2013 .
[94] Sarah Callaghan,et al. The METAFOR Project , 2013 .
[95] P Glasziou,et al. Meta-analytic methods for diagnostic test accuracy. , 1995, Journal of clinical epidemiology.